Aminoglycosides Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Aminoglycosides DMPK and Bioanalytical Services

Aminoglycoside bioanalysis is not a routine small-molecule LC-MS/MS task. These antibiotics are highly polar, polycationic, and rich in amino and hydroxyl groups, which creates a very different analytical problem from β-lactams, macrolides, or fluoroquinolones. The bottleneck is often not compound detection alone, but chromatographic retention, matrix cleanup, ion suppression, recovery, broad concentration ranges, and whether the assay can support renal-excretion and exposure-linked research interpretation.

For aminoglycoside DMPK studies, the central question is not simply whether gentamicin, amikacin, tobramycin, streptomycin, or neomycin can be measured. The real challenge is whether the method can handle highly polar cationic analytes across serum, plasma, urine, tissue, renal models, or intracellular samples while preserving selectivity, sensitivity, dilution integrity, and compatibility with multi-analyte aminoglycoside panels.

Browse Aminoglycoside Drug Index Request Custom Aminoglycoside Method Support

Highly polar analytesBuild retention-aware LC-MS/MS workflows before polarity breaks the assay.

Renal exposure focusPlan serum, plasma, urine, and kidney tissue workflows around matrix-specific burden.

Peak / trough windowsSupport concentration-dependent exposure interpretation across broad dynamic ranges.

Aminoglycoside Workflow Risks DMPK Strategy Map

⚗

Polar cationic structurePoor reversed-phase retention, early elution, and matrix suppression can dominate method design.

🧪

Matrix-specific burdenSerum, plasma, urine, kidney tissue, and local matrices may need separate controls.

📈

Peak / trough coverageCalibration, LLOQ, dilution, and carryover strategy must cover the full exposure window.

🧬

Research readout integrationConcentration data may need renal, tissue, or model-specific safety readouts beside it.

Retention-aware aminoglycoside workflow design.Creative Proteomics connects polar-analyte LC-MS/MS method development, serum/plasma/urine bioanalysis, renal exposure profiling, tissue accumulation, research biomarker support, and custom aminoglycoside panels in one study-aware strategy.

Aminoglycoside Drug Index

Find the Aminoglycoside Behind the Study

If you are struggling with zero retention on a polar-analyte LC-MS/MS run or decoding critical peak and trough sampling gaps in renal exposure models, a generic category tree won't help you. Use the search bar, filter via A–Z, or stack field tags below to bypass the standard navigation and instantly lock onto the exact aminoglycoside chromatography and sample-prep protocols your validation requires.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only aminoglycosides matching all selected values.

5 entries · Page 1 of 2

Analytical Pain Points

What Drives Assay Failure in Aminoglycoside Studies?

Aminoglycoside DMPK studies often fail when the assay is treated as a routine hydrophobic small-molecule LC-MS/MS method. These compounds are highly polar, cationic, and matrix-sensitive. They can show poor reversed-phase retention, strong interaction with biological matrices, ion suppression, recovery variability, and large concentration differences across serum, plasma, urine, kidney tissue, and local sample types.

Highly Polar Cationic Analytes Can Break Generic LC-MS/MS Methods

Aminoglycosides are not easy reversed-phase analytes. Their polar, polycationic structures can lead to weak retention, broad peaks, early elution, ion suppression, and inconsistent recovery if the LC-MS/MS method is copied from a more hydrophobic drug class.

Our responseRetention-aware LC-MS/MS workflows using HILIC-compatible conditions, ion-pairing-aware workflows, derivatization-aware approaches when appropriate, matrix-matched calibration, and cleanup designed for highly polar aminoglycosides.

LC-MS/MS Quantification →

Serum, Plasma, Urine, and Kidney Tissue Create Different Matrix Burdens

Urine can require dilution and carryover control; kidney tissue can require homogenization and recovery optimization; serum and plasma can require sensitivity and matrix effect control. A single generic workflow may fail when transferred across matrices without validation.

Our responseMatrix-specific sample preparation, calibration, recovery evaluation, dilution integrity, carryover control, and ion suppression assessment for each required biological matrix.

Plasma & Serum Bioanalysis →

Renal Excretion and Accumulation Drive the Study Design

Many aminoglycoside studies are built around renal elimination and renal exposure. If the method ignores unchanged urinary recovery, kidney tissue accumulation, broad concentration windows, or renal biomarker research integration, the data may not support the intended DMPK interpretation.

Our responseRenal-excretion and renal-accumulation workflows that can include urine analysis, kidney tissue quantification, concentration-window planning, and optional research biomarker support for renal injury models.

Tissue & Cell Lysate Quantification →

Cmax/MIC and Peak / Trough Context Requires Wide Concentration-Window Planning

Aminoglycosides are commonly interpreted through concentration-dependent exposure concepts such as Cmax/MIC and peak / trough profiles in research settings. The method must cover the entire exposure window, not only a convenient calibration range.

Our responseCalibration ranges, LLOQ strategy, dilution plans, carryover controls, and sampling-compatible workflows around expected peak, trough, urine, and tissue concentration windows.

LC-MS/MS Quantification →

Multi-Aminoglycoside Panels Require Component-Level Selectivity

Gentamicin and neomycin can involve mixtures or closely related components, while other aminoglycosides share polar scaffold behavior. A panel must resolve related structures, manage ion suppression, and maintain sensitivity across analytes.

Our responseCustom LC-MS/MS panels considering component-level selectivity, extraction strategy, chromatographic retention, MRM transitions, internal standards, matrix-matched calibration, and dilution integrity.

Custom Drug Panels →

Focused Service Paths

Four Practical Routes for Aminoglycoside Studies

Instead of treating aminoglycosides as one generic antibiotic class, the analytical route should be selected according to the study objective: parent-drug exposure, renal excretion, matrix-specific accumulation, peak / trough research interpretation, safety biomarker research support, or custom panel development.

Parent Aminoglycoside PK and Exposure Profiling

For studies that require parent-drug concentration data in serum, plasma, urine, tissue, cell lysate, or another biological matrix.

Gentamicin, amikacin, tobramycin, streptomycin, or neomycin quantification
Serum or plasma exposure profiling
Peak / trough research sample sets
Highly polar analyte method development

LC-MS/MS Drug Quantification →

Renal Excretion and Kidney Tissue Workflow Design

For studies where urine concentration, renal clearance, kidney tissue accumulation, dilution integrity, or matrix-specific recovery defines the analytical problem.

Gentamicin renal exposure studies
Amikacin urine and renal-excretion workflows
Tobramycin serum / urine studies
Kidney tissue concentration analysis

Plasma & Serum Bioanalysis →

Exposure-Linked Biomarker and Tissue Distribution Support

For studies where concentration data must be interpreted alongside renal tissue accumulation, renal safety research biomarkers, auditory safety research markers, oxidative stress readouts, or model-specific tissue distribution.

Kidney tissue or renal model studies
Renal safety biomarker-linked workflows
Auditory safety research readouts
Tissue homogenate or cell lysate analysis

Tissue & Cell Lysate Quantification →

Aminoglycoside Panel and Component-Level Method Development

For studies involving multiple aminoglycosides, component-rich materials, comparative exposure analysis, or broader anti-infective panels.

Multi-aminoglycoside quantification
Gentamicin or neomycin component-aware workflows
Comparative anti-infective exposure studies
Custom MRM and chromatographic selectivity planning

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Aminoglycoside?

If you are working with an aminoglycoside analog, a semi-synthetic derivative, a component-rich material, a renal model, a tissue-specific sample type, or a complex biological matrix, a standard parent-drug method may not be enough.

Creative Proteomics develops custom LC-MS/MS and DMPK workflows for challenging aminoglycoside and anti-infective analytes. Share your target aminoglycoside, matrix, expected concentration range, renal exposure focus, tissue or research biomarker readouts, and panel requirements to initiate a feasibility review.

Highly polar analyte behavior

Serum / urine concentration range

Renal exposure focus

Tissue or biomarker readouts

Matrix cleanup and ion suppression

Single-analyte assay or panel workflow